|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.  We would like to hear your views on these questions:   1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why. 2. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.) 3. The current title of this guideline is Neurological problems: Assessment, diagnosis and referral. There is a need for guidance that helps non-specialists recognise the symptoms that may indicate a neurological problem, and guides them in assessing people and making decisions about whether referral to specialist care is appropriate. The diagnosis of neurological conditions should be carried out or confirmed by neurological specialists, following referral, so including diagnosis within the remit of this guideline is considered to be of limited practical value. Given the suggested focus of this guideline, the following revised title has been proposed - **Suspected neurological conditions: Recognition and referral**. Do you agree with the proposed change to the guideline title? 4. We are planning to construct our literature searches around these condition groups to identify features, signs and symptoms of concern - are any important condition groups missing from this list? Please provide a rationale for your response.   4.1 Adults  Movement disorders including tremors, dystonia and gait apraxia  Neuromuscular conditions including myopathies, myasthenia and muscular dystrophies  Functional disorders including non-epileptic dissociative seizures  Neuropathies including entrapment neuropathies and Guillain-Barre syndrome  Radiculopathies  4.2 Children and young people  Movement disorders including dystonia  Neuromuscular conditions including myopathies, myasthenia and muscular dystrophies  Brain tumours  Guillain-Barre syndrome  Neurodegenerative conditions  See section 3.9 of [Developing NICE guidance: how to get involved](https://www.nice.org.uk/article/pmg22/chapter/3-how-you-can-get-involved#draft-guideline-consultation) for suggestions of general points to think about when commenting. | | |
| Stakeholder organisation(s) (or your name if you are commenting as an individual): | | **[insert name of organisation here]** | | |
| Name of commentator (leave blank if you are commenting as an individual): | | **[insert your name here]** | | |
| **Comment number** | **Document**  **(full** version,  **short** version or the **appendices** | Page number  Or **‘general’** for comments on the whole document | Line number  Or **‘general’** for comments on the whole document | Comments Insert each comment in a new row.  Do not paste other tables into this table, because your comments could get lost – type directly into this table. |
| Example 1 | Full | 16 | 45 | We are concerned that this recommendation may imply that ………….. |
| Example 2 | Full | 16 | 45 | Question 1: This recommendation will be a challenging change in practice because …… |
| Example 3 | Full | 16 | 45 | Question 2: Our trust has had experience of implementing this approach and would be willing to submit its experiences to the NICE shared learning database. Contact………………. |
|  | | | | |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |
| 7 |  |  |  |  |
| 8 |  |  |  |  |
| 9 |  |  |  |  |
| 10 |  |  |  |  |
| 11 |  |  |  |  |
| 12 |  |  |  |  |
| 13 |  |  |  |  |
| 14 |  |  |  |  |
| 15 |  |  |  |  |
| 16 |  |  |  |  |
| 17 |  |  |  |  |
| 18 |  |  |  |  |
| 19 |  |  |  |  |
| 20 |  |  |  |  |

Insert extra rows as needed

|  |
| --- |
| **Checklist for submitting comments**   * Use this comment form and submit it as a Word document (not a PDF). * Include page and line number (not section number) of the text each comment is about. * Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation. * Do not paste other tables into this table – type directly into the table. * Underline and highlight any confidential information or other material that you do not wish to be made public. * Do not include medical information about yourself or another person from which you or the person could be identified. * Spell out any abbreviations you use * For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.   You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](http://pathways.nice.org.uk/).  **Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.  Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. |